Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in United Therapeutics Corporation, Ginkgo Bioworks Holdings or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how United Therapeutics Corporation, Ginkgo Bioworks Holdings and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About United Therapeutics Corporation, Ginkgo Bioworks Holdings and Inc.

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Latest Biotechnology and United Therapeutics Corporation, Ginkgo Bioworks Holdings, Inc. Stock News

As of September 4, 2026, United Therapeutics Corporation had a $20.9 billion market capitalization, compared to the Biotechnology median of $282.4 million. United Therapeutics Corporation’s stock is up 0.1% in 2026, down 5.4% in the previous five trading days and up 28.16% in the past year.

Currently, United Therapeutics Corporation’s price-earnings ratio is 17.4. United Therapeutics Corporation’s trailing 12-month revenue is $3.2 billion with a 41.6% net profit margin. Year-over-year quarterly sales growth most recently was -1.9%. Analysts expect adjusted earnings to reach $27.574 per share for the current fiscal year. United Therapeutics Corporation does not currently pay a dividend.

As of September 4, 2026, Ginkgo Bioworks Holdings, Inc. had a $468.0 million market cap, putting it in the 36th percentile of all stocks. Ginkgo Bioworks Holdings, Inc.’s stock is down 16.4% in 2026, down 0.1% in the previous five trading days and down 40.5% in the past year.

Currently, Ginkgo Bioworks Holdings, Inc. does not have a price-earnings ratio. Ginkgo Bioworks Holdings, Inc.’s trailing 12-month revenue is $132.4 million with a -219.6% net profit margin. Year-over-year quarterly sales growth most recently was -48.3%. Analysts expect adjusted earnings to reach $-3.200 per share for the current fiscal year. Ginkgo Bioworks Holdings, Inc. does not currently pay a dividend.

How We Compare United Therapeutics Corporation, Ginkgo Bioworks Holdings and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at United Therapeutics Corporation, Ginkgo Bioworks Holdings and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

United Therapeutics Corporation, Ginkgo Bioworks Holdings and Inc. Growth Grades

Company	Ticker	Growth
United Therapeutics Corporation	UTHR	A
Ginkgo Bioworks Holdings, Inc.	DNA	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

United Therapeutics Corporation has a Growth Score of 89, which is Very Strong. Ginkgo Bioworks Holdings, Inc. has a Growth Score of 14, which is Very Weak.

The Growth Grade Winner: United Therapeutics Corporation

As you can clearly see from the Growth Grade breakdown above, United Therapeutics Corporation has a more attractive growth grade than Ginkgo Bioworks Holdings, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, United Therapeutics Corporation could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

United Therapeutics Corporation, Ginkgo Bioworks Holdings and Inc.’s Quality Grades

Company	Ticker	Quality
United Therapeutics Corporation	UTHR	A
Ginkgo Bioworks Holdings, Inc.	DNA	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

United Therapeutics Corporation has a Quality Score of 95, which is Very Strong. Ginkgo Bioworks Holdings, Inc. has a Quality Score of 22, which is Weak.

The Quality Grade Winner: United Therapeutics Corporation

As you can clearly see from the Quality Grade breakdown above, United Therapeutics Corporation has a better overall quality grade than Ginkgo Bioworks Holdings, Inc.. For investors who are looking for companies with higher quality than others in the same industry, United Therapeutics Corporation could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

United Therapeutics Corporation, Ginkgo Bioworks Holdings and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
United Therapeutics Corporation	UTHR	C
Ginkgo Bioworks Holdings, Inc.	DNA	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

United Therapeutics Corporation has a Earnings Estimate Score of 41, which is Neutral. Ginkgo Bioworks Holdings, Inc. has a Earnings Estimate Score of 79, which is Positive.

The Earnings Estimate Revisions Grade Winner: Ginkgo Bioworks Holdings, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Ginkgo Bioworks Holdings, Inc. has a better Earnings Estimate Revisions Grade than United Therapeutics Corporation. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Ginkgo Bioworks Holdings, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other United Therapeutics Corporation, Ginkgo Bioworks Holdings and Inc. Grades

In addition to Quality, Estimate Revisions and Growth, A+ Investor also provides grades for Value and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether United Therapeutics Corporation, Ginkgo Bioworks Holdings and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, United Therapeutics Corporation, Ginkgo Bioworks Holdings or Inc. Stock?

Overall, United Therapeutics Corporation stock has a Growth Score of 89, Estimate Revisions Score of 41 and Quality Score of 95.

Ginkgo Bioworks Holdings, Inc. stock has a Growth Score of 14, Estimate Revisions Score of 79 and Quality Score of 22.

Comparing United Therapeutics Corporation, Ginkgo Bioworks Holdings and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.